{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T16:16:20Z","timestamp":1773850580803,"version":"3.50.1"},"reference-count":135,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,6,1]],"date-time":"2020-06-01T00:00:00Z","timestamp":1590969600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,6,1]],"date-time":"2020-06-01T00:00:00Z","timestamp":1590969600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,3,18]],"date-time":"2020-03-18T00:00:00Z","timestamp":1584489600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedicine & Pharmacotherapy"],"published-print":{"date-parts":[[2020,6]]},"DOI":"10.1016\/j.biopha.2020.110107","type":"journal-article","created":{"date-parts":[[2020,4,1]],"date-time":"2020-04-01T16:48:53Z","timestamp":1585759733000},"page":"110107","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"special_numbering":"C","title":["Current understandings on T-cell prolymphocytic leukemia and its association with TCL1 proto-oncogene"],"prefix":"10.1016","volume":"126","author":[{"given":"Siyu","family":"Sun","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wenjia","family":"Fang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.biopha.2020.110107_bib0005","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1385\/MO:23:1:17","article-title":"T-cell prolymphocytic leukemia","volume":"23","author":"Dearden","year":"2006","journal-title":"Med. Oncol."},{"issue":"1","key":"10.1016\/j.biopha.2020.110107_bib0010","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1186\/2162-3619-1-21","article-title":"T-cell prolymphocytic leukemia (T-PLL), a heterogeneous disease exemplified by two cases and the important role of cytogenetics: a multidisciplinary approach","volume":"1","author":"Tirado","year":"2012","journal-title":"Exp. Hematol. Oncol."},{"issue":"12","key":"10.1016\/j.biopha.2020.110107_bib0015","doi-asserted-by":"crossref","first-page":"3269","DOI":"10.1182\/blood.V78.12.3269.3269","article-title":"Clinical and laboratory features of 78 cases of T-prolymphocytic leukemia","volume":"78","author":"Matutes","year":"1991","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.biopha.2020.110107_bib0020","first-page":"301","article-title":"Exploring the molecular pathogenesis associated with T-cell prolymphocytic leukemia based on a comprehensive bioinformatics analysis","volume":"16","author":"Shi","year":"2018","journal-title":"Oncol. Lett."},{"issue":"4","key":"10.1016\/j.biopha.2020.110107_bib0025","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1182\/blood.V70.4.926.926","article-title":"Cytogenetic studies on prolymphocytic leukemia. II. T cell prolymphocytic leukemia","volume":"70","author":"Brito-Babapulle","year":"1987","journal-title":"Blood"},{"issue":"24","key":"10.1016\/j.biopha.2020.110107_bib0030","first-page":"5452","article-title":"TCL1 is overexpressed in patients affected by adult T-cell leukemias","volume":"57","author":"Narducci","year":"1997","journal-title":"Cancer Res."},{"issue":"7823","key":"10.1016\/j.biopha.2020.110107_bib0035","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1016\/S0140-6736(73)93135-8","article-title":"Prolymphocytic leukaemia of B and T cell type","volume":"2","author":"Catovsky","year":"1973","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.biopha.2020.110107_bib0040","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1046\/j.1365-2141.1998.00977.x","article-title":"Indolent course as a relatively frequent presentation in T-prolymphocytic leukaemia. Groupe Francais d\u2019Hematologie Cellulaire","volume":"103","author":"Garand","year":"1998","journal-title":"Br. J. Haematol."},{"issue":"2015","key":"10.1016\/j.biopha.2020.110107_bib0045","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1182\/asheducation.V2015.1.361.3917560","article-title":"Management of prolymphocytic leukemia","volume":"1","author":"Dearden","year":"2015","journal-title":"Hematology Am. Soc. Hematol. Educ. Program"},{"issue":"5","key":"10.1016\/j.biopha.2020.110107_bib0050","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1309\/AJCPG71KYOXTKLQW","article-title":"Immunophenotypic characterization of T-Cell prolymphocytic leukemia","volume":"140","author":"Chen","year":"2013","journal-title":"Am. J. Clin. Pathol."},{"key":"10.1016\/j.biopha.2020.110107_bib0055","series-title":"Chronic Lymphoid Leukemias","author":"Cheson","year":"2001"},{"issue":"2","key":"10.1016\/j.biopha.2020.110107_bib0060","first-page":"586","article-title":"WHO classification of tumours of haematopoietic and lymphoid tissues. Revised fourth edition","volume":"2","author":"Swerdlow","year":"2017","journal-title":"IARC Pub."},{"issue":"1","key":"10.1016\/j.biopha.2020.110107_bib0065","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1111\/j.1365-2141.1986.tb07579.x","article-title":"The morphological spectrum of T-prolymphocytic leukaemia","volume":"64","author":"Matutes","year":"1986","journal-title":"Br. J. Haematol."},{"issue":"3","key":"10.1016\/j.biopha.2020.110107_bib0070","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1182\/blood-2012-01-380139","article-title":"How I treat prolymphocytic leukemia","volume":"120","author":"Dearden","year":"2012","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.biopha.2020.110107_bib0075","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/S0145-2126(97)00158-6","article-title":"Levels of expression of CD52 in normal and leukemic B and T cells: correlation with in vivo therapeutic responses to Campath-1H","volume":"22","author":"Ginaldi","year":"1998","journal-title":"Leuk. Res."},{"issue":"12","key":"10.1016\/j.biopha.2020.110107_bib0080","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1007\/s00277-001-0381-z","article-title":"T-cell receptor gammadelta T-cell leukemia with the morphology of T-cell prolymphocytic leukemia and a postthymic immunophenotype","volume":"80","author":"Sugimoto","year":"2001","journal-title":"Ann. Hematol."},{"issue":"2","key":"10.1016\/j.biopha.2020.110107_bib0085","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1046\/j.1365-2141.1998.00977.x","article-title":"Indolent course as a relatively frequent presentation in T-prolymphocytic leukaemia","volume":"103","author":"Garand","year":"1998","journal-title":"Br. J. Haematol."},{"issue":"18","key":"10.1016\/j.biopha.2020.110107_bib0090","doi-asserted-by":"crossref","first-page":"2308","DOI":"10.1001\/jama.286.18.2308","article-title":"Molecular basis of mature T-cell leukemia","volume":"286","author":"Pekarsky","year":"2001","journal-title":"JAMA"},{"issue":"1","key":"10.1016\/j.biopha.2020.110107_bib0095","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/0165-4608(94)90040-X","article-title":"Recurrent chromosome abnormalities in peripheral T-cell lymphomas","volume":"78","author":"Schlegelberger","year":"1994","journal-title":"Cancer Genet. Cytogenet."},{"key":"10.1016\/j.biopha.2020.110107_bib0100","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1146\/annurev.ge.21.120187.001541","article-title":"Oncogene activation by chromosome translocation in human malignancy","volume":"21","author":"Haluska","year":"1987","journal-title":"Annu. Rev. Genet."},{"issue":"40","key":"10.1016\/j.biopha.2020.110107_bib0105","doi-asserted-by":"crossref","first-page":"5638","DOI":"10.1038\/sj.onc.1204596","article-title":"The role of TCL1 in human T-cell leukemia","volume":"20","author":"Pekarsky","year":"2001","journal-title":"Oncogene"},{"issue":"9","key":"10.1016\/j.biopha.2020.110107_bib0110","first-page":"2475","article-title":"MTCP-1: a novel gene on the human chromosome Xq28 translocated to the T cell receptor alpha\/delta locus in mature T cell proliferations","volume":"8","author":"Stern","year":"1993","journal-title":"Oncogene"},{"issue":"2","key":"10.1016\/j.biopha.2020.110107_bib0115","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/S0165-4608(97)00410-X","article-title":"Abnormalities of chromosomes 8, 11, 14, and X in T-prolymphocytic leukemia studied by fluorescence in situ hybridization","volume":"103","author":"Maljaei","year":"1998","journal-title":"Cancer Genet. Cytogenet."},{"issue":"7","key":"10.1016\/j.biopha.2020.110107_bib0120","doi-asserted-by":"crossref","first-page":"1554","DOI":"10.1093\/annonc\/mdx163","article-title":"Characteristics, outcomes, prognostic factors and treatment of patients with T-cell prolymphocytic leukemia (T-PLL)","volume":"28","author":"Jain","year":"2017","journal-title":"Ann. Oncol."},{"issue":"1","key":"10.1016\/j.biopha.2020.110107_bib0125","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/0165-4608(94)90042-6","article-title":"Multiple karyotypic abnormalities in three cases of small cell variant of T-cell prolymphocytic leukemia","volume":"78","author":"Heinonen","year":"1994","journal-title":"Cancer Genet. Cytogenet."},{"issue":"1","key":"10.1016\/j.biopha.2020.110107_bib0130","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0165-4608(91)90228-M","article-title":"Inversions and tandem translocations involving chromosome 14q11 and 14q32 in T-prolymphocytic leukemia and T-cell leukemias in patients with ataxia telangiectasia","volume":"55","author":"Brito-Babapulle","year":"1991","journal-title":"Cancer Genet. Cytogenet."},{"issue":"3","key":"10.1016\/j.biopha.2020.110107_bib0135","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1002\/gcc.1141","article-title":"A complex pattern of recurrent chromosomal losses and gains in T-cell prolymphocytic leukemia","volume":"31","author":"Soulier","year":"2001","journal-title":"Genes Chromosomes Cancer"},{"issue":"26","key":"10.1016\/j.biopha.2020.110107_bib0140","doi-asserted-by":"crossref","first-page":"12530","DOI":"10.1073\/pnas.91.26.12530","article-title":"Identification of the TCL1 gene involved in T-cell malignancies","volume":"91","author":"Virgilio","year":"1994","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"8","key":"10.1016\/j.biopha.2020.110107_bib0145","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1038\/sj.onc.1201246","article-title":"The murine Tcl1 oncogene: embryonic and lymphoid cell expression","volume":"15","author":"Narducci","year":"1997","journal-title":"Oncogene"},{"issue":"3","key":"10.1016\/j.biopha.2020.110107_bib0150","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1182\/blood-2004-04-1453","article-title":"Impaired T- and B-cell development in Tcl1-deficient mice","volume":"105","author":"Kang","year":"2005","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.biopha.2020.110107_bib0155","doi-asserted-by":"crossref","first-page":"3028","DOI":"10.1073\/pnas.97.7.3028","article-title":"Tcl1 enhances Akt kinase activity and mediates its nuclear translocation","volume":"97","author":"Pekarsky","year":"2000","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"34","key":"10.1016\/j.biopha.2020.110107_bib0160","doi-asserted-by":"crossref","first-page":"35890","DOI":"10.1074\/jbc.M400364200","article-title":"Structural basis for the co-activation of protein kinase B by T-cell leukemia-1 (TCL1) family proto-oncoproteins","volume":"279","author":"Auguin","year":"2004","journal-title":"J. Biol. Chem."},{"issue":"2","key":"10.1016\/j.biopha.2020.110107_bib0165","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/S1097-2765(00)00039-3","article-title":"The protooncogene TCL1 is an Akt kinase coactivator","volume":"6","author":"Laine","year":"2000","journal-title":"Mol. Cell"},{"issue":"3","key":"10.1016\/j.biopha.2020.110107_bib0170","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/S1471-4906(03)00022-X","article-title":"Akt is TCL-ish: implications for B-cell lymphoma","volume":"24","author":"Gold","year":"2003","journal-title":"Trends Immunol."},{"issue":"17","key":"10.1016\/j.biopha.2020.110107_bib0175","doi-asserted-by":"crossref","first-page":"2203","DOI":"10.1101\/gad.913901","article-title":"Growth retardation and increased apoptosis in mice with homozygous disruption of the Akt1 gene","volume":"15","author":"Chen","year":"2001","journal-title":"Genes Dev."},{"key":"10.1016\/j.biopha.2020.110107_bib0180","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1146\/annurev.biochem.68.1.965","article-title":"AKT\/PKB and other D3 phosphoinositide-regulated kinases: kinase activation by phosphoinositide-dependent phosphorylation","volume":"68","author":"Chan","year":"1999","journal-title":"Annu. Rev. Biochem."},{"issue":"4","key":"10.1016\/j.biopha.2020.110107_bib0185","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/S1535-6108(03)00248-4","article-title":"Targeting the PI3K-Akt pathway in human cancer: rationale and promise","volume":"4","author":"Luo","year":"2003","journal-title":"Cancer Cell"},{"issue":"1","key":"10.1016\/j.biopha.2020.110107_bib0190","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1182\/blood-2007-07-101519","article-title":"High TCL1 expression and intact T-cell receptor signaling define a hyperproliferative subset of T-cell prolymphocytic leukemia","volume":"111","author":"Herling","year":"2008","journal-title":"Blood"},{"issue":"61","key":"10.1016\/j.biopha.2020.110107_bib0195","doi-asserted-by":"crossref","first-page":"104664","DOI":"10.18632\/oncotarget.22272","article-title":"Advances in the understanding and management of T-cell prolymphocytic leukemia","volume":"8","author":"Laribi","year":"2017","journal-title":"Oncotarget"},{"issue":"8","key":"10.1016\/j.biopha.2020.110107_bib0200","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1038\/nrc1672","article-title":"The TCL1 family of oncoproteins: co-activators of transformation","volume":"5","author":"Teitell","year":"2005","journal-title":"Nat. Rev. Cancer"},{"issue":"5","key":"10.1016\/j.biopha.2020.110107_bib0205","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1128\/MCB.22.5.1513-1525.2002","article-title":"Identification of Akt association and oligomerization domains of the Akt kinase coactivator TCL1","volume":"22","author":"Kunstle","year":"2002","journal-title":"Mol. Cell. Biol."},{"issue":"7","key":"10.1016\/j.biopha.2020.110107_bib0210","doi-asserted-by":"crossref","first-page":"3885","DOI":"10.1073\/pnas.95.7.3885","article-title":"Deregulated expression of TCL1 causes T cell leukemia in mice","volume":"95","author":"Virgilio","year":"1998","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"2","key":"10.1016\/j.biopha.2020.110107_bib0215","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1182\/blood.V92.2.368","article-title":"Transgenic mice for MTCP1 develop T-cell prolymphocytic leukemia","volume":"92","author":"Gritti","year":"1998","journal-title":"Blood"},{"issue":"22","key":"10.1016\/j.biopha.2020.110107_bib0220","doi-asserted-by":"crossref","first-page":"14392","DOI":"10.1073\/pnas.212410199","article-title":"Dysregulated TCL1 promotes multiple classes of mature B cell lymphoma","volume":"99","author":"Hoyer","year":"2002","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"10","key":"10.1016\/j.biopha.2020.110107_bib0225","doi-asserted-by":"crossref","first-page":"2273","DOI":"10.1096\/fj.06-7684com","article-title":"Proto-oncogene TCL1: more than just a coactivator for Akt","volume":"21","author":"Noguchi","year":"2007","journal-title":"Faseb J."},{"issue":"10","key":"10.1016\/j.biopha.2020.110107_bib0230","doi-asserted-by":"crossref","first-page":"2153","DOI":"10.1038\/sj.leu.2404877","article-title":"Combined single nucleotide polymorphism-based genomic mapping and global gene expression profiling identifies novel chromosomal imbalances, mechanisms and candidate genes important in the pathogenesis of T-cell prolymphocytic leukemia with inv(14)(q11q32)","volume":"21","author":"Durig","year":"2007","journal-title":"Leukemia"},{"issue":"4","key":"10.1016\/j.biopha.2020.110107_bib0235","doi-asserted-by":"crossref","first-page":"518","DOI":"10.3324\/haematol.2008.001347","article-title":"Molecular allelokaryotyping of T-cell prolymphocytic leukemia cells with high density single nucleotide polymorphism arrays identifies novel common genomic lesions and acquired uniparental disomy","volume":"94","author":"Nowak","year":"2009","journal-title":"Haematologica"},{"issue":"3","key":"10.1016\/j.biopha.2020.110107_bib0240","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1111\/pai.13020","article-title":"Ataxia-telangiectasia: A review of clinical features and molecular pathology","volume":"30","author":"Amirifar","year":"2019","journal-title":"Pediatr. Allergy Immunol."},{"issue":"3","key":"10.1016\/j.biopha.2020.110107_bib0245","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1182\/blood-2016-01-691550","article-title":"Complex karyotypes and KRAS and POT1 mutations impact outcome in CLL after chlorambucil-based chemotherapy or chemoimmunotherapy","volume":"128","author":"Herling","year":"2016","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.biopha.2020.110107_bib0250","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1002\/gcc.22123","article-title":"Complex karyotype in mantle cell lymphoma is a strong prognostic factor for the time to treatment and overall survival, independent of the MCL international prognostic index","volume":"53","author":"Sarkozy","year":"2014","journal-title":"Genes Chromosomes Cancer"},{"issue":"13","key":"10.1016\/j.biopha.2020.110107_bib0255","doi-asserted-by":"crossref","first-page":"2607","DOI":"10.1200\/JCO.2000.18.13.2607","article-title":"Acquired chromosome 11q deletion involving the Ataxia teleangiectasia locus in B-Cell Non-Hodgkin\u2019s lymphoma: correlation with clinicobiologic features","volume":"18","author":"Cuneo","year":"2000","journal-title":"J. Clin. Oncol."},{"issue":"4690","key":"10.1016\/j.biopha.2020.110107_bib0260","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1126\/science.3919442","article-title":"Gene for alpha-chain of human T-cell receptor: location on chromosome 14 region involved in T-cell neoplasms","volume":"227","author":"Croce","year":"1985","journal-title":"Science"},{"issue":"6","key":"10.1016\/j.biopha.2020.110107_bib0265","doi-asserted-by":"crossref","first-page":"2949","DOI":"10.1073\/pnas.96.6.2949","article-title":"Abnormalities at 14q32.1 in T cell malignancies involve two oncogenes","volume":"96","author":"Pekarsky","year":"1999","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"25","key":"10.1016\/j.biopha.2020.110107_bib0270","doi-asserted-by":"crossref","first-page":"14418","DOI":"10.1073\/pnas.96.25.14418","article-title":"Genomic analysis of human and mouse TCL1 loci reveals a complex of tightly clustered genes","volume":"96","author":"Hallas","year":"1999","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"18","key":"10.1016\/j.biopha.2020.110107_bib0275","doi-asserted-by":"crossref","first-page":"11712","DOI":"10.1073\/pnas.182412399","article-title":"TCL1 participates in early embryonic development and is overexpressed in human seminomas","volume":"99","author":"Narducci","year":"2002","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"12","key":"10.1016\/j.biopha.2020.110107_bib0280","doi-asserted-by":"crossref","first-page":"5007","DOI":"10.1182\/blood-2002-10-3297","article-title":"TCL1 expression in plasmacytoid dendritic cells (DC2s) and the related CD4+ CD56+ blastic tumors of skin","volume":"101","author":"Herling","year":"2003","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.biopha.2020.110107_bib0285","doi-asserted-by":"crossref","first-page":"1923","DOI":"10.1182\/blood.V87.5.1923.1923","article-title":"Expression of p13MTCP1 is restricted to mature T-cell proliferations with t(X;14) translocations","volume":"87","author":"Madani","year":"1996","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.biopha.2020.110107_bib0290","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0204775","article-title":"T Cell Leukemia\/Lymphoma 1A is essential for mouse epidermal keratinocytes proliferation promoted by insulin-like growth factor 1","volume":"13","author":"Bresin","year":"2018","journal-title":"PLoS One"},{"key":"10.1016\/j.biopha.2020.110107_bib0295","doi-asserted-by":"crossref","first-page":"317","DOI":"10.3389\/fonc.2018.00317","article-title":"T-cell Leukemia\/Lymphoma 1 (TCL1): an oncogene regulating multiple signaling pathways","volume":"8","author":"Paduano","year":"2018","journal-title":"Front. Oncol."},{"issue":"2","key":"10.1016\/j.biopha.2020.110107_bib0300","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1073\/pnas.86.2.602","article-title":"Molecular analysis of a t(14;14) translocation in leukemic T-cells of an ataxia telangiectasia patient","volume":"86","author":"Russo","year":"1989","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"24","key":"10.1016\/j.biopha.2020.110107_bib0305","doi-asserted-by":"crossref","first-page":"9069","DOI":"10.1073\/pnas.84.24.9069","article-title":"The breakpoint of an inversion of chromosome 14 in a T-cell leukemia: sequences downstream of the immunoglobulin heavy chain locus are implicated in tumorigenesis","volume":"84","author":"Baer","year":"1987","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"8","key":"10.1016\/j.biopha.2020.110107_bib0310","doi-asserted-by":"crossref","first-page":"2273","DOI":"10.1002\/j.1460-2075.1987.tb02501.x","article-title":"Human T-cell tumours containing chromosome 14 inversion or translocation with breakpoints proximal to immunoglobulin joining regions at 14q32","volume":"6","author":"Mengle-Gaw","year":"1987","journal-title":"EMBO J."},{"issue":"2","key":"10.1016\/j.biopha.2020.110107_bib0315","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/S0969-2126(98)00017-3","article-title":"Crystal structure of p14TCL1, an oncogene product involved in T-cell prolymphocytic leukemia, reveals a novel beta-barrel topology","volume":"6","author":"Hoh","year":"1998","journal-title":"Structure"},{"issue":"3","key":"10.1016\/j.biopha.2020.110107_bib0320","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1023\/A:1008279616063","article-title":"Solution structure of the recombinant human oncoprotein p13MTCP1","volume":"11","author":"Yang","year":"1998","journal-title":"J. Biomol. NMR"},{"issue":"5","key":"10.1016\/j.biopha.2020.110107_bib0325","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1006\/jmbi.1997.1438","article-title":"Solution structure of human p8MTCP1, a cysteine-rich protein encoded by the MTCP1 oncogene, reveals a new alpha-helical assembly motif","volume":"274","author":"Barthe","year":"1997","journal-title":"J. Mol. Biol."},{"issue":"11","key":"10.1016\/j.biopha.2020.110107_bib0330","first-page":"2259","article-title":"The 8 kD product of the putative oncogene MTCP-1 is a mitochondrial protein","volume":"10","author":"Madani","year":"1995","journal-title":"Oncogene"},{"issue":"7","key":"10.1016\/j.biopha.2020.110107_bib0335","doi-asserted-by":"crossref","first-page":"3413","DOI":"10.1073\/pnas.95.7.3413","article-title":"Crystal structure of MTCP-1: implications for role of TCL-1 and MTCP-1 in T cell malignancies","volume":"95","author":"Fu","year":"1998","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"Pt 1","key":"10.1016\/j.biopha.2020.110107_bib0340","first-page":"1","article-title":"The lipocalin protein family: structure and function","volume":"318","author":"Flower","year":"1996","journal-title":"Biochem. J."},{"issue":"8","key":"10.1016\/j.biopha.2020.110107_bib0345","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1038\/nrg1879","article-title":"The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism","volume":"7","author":"Engelman","year":"2006","journal-title":"Nat. Rev. Genet."},{"issue":"1","key":"10.1016\/j.biopha.2020.110107_bib0350","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1111\/j.1582-4934.2005.tb00337.x","article-title":"The activation of Akt\/PKB signaling pathway and cell survival","volume":"9","author":"Song","year":"2005","journal-title":"J. Cell. Mol. Med."},{"issue":"1","key":"10.1016\/j.biopha.2020.110107_bib0355","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1038\/nrm2822","article-title":"The nuts and bolts of AGC protein kinases","volume":"11","author":"Pearce","year":"2010","journal-title":"Nat. Rev. Mol. Cell Biol."},{"issue":"20","key":"10.1016\/j.biopha.2020.110107_bib0360","doi-asserted-by":"crossref","first-page":"6376","DOI":"10.1021\/bi016068o","article-title":"A modeled hydrophobic domain on the TCL1 oncoprotein mediates association with AKT at the cytoplasmic membrane","volume":"41","author":"French","year":"2002","journal-title":"Biochemistry"},{"issue":"5","key":"10.1016\/j.biopha.2020.110107_bib0365","doi-asserted-by":"crossref","first-page":"3743","DOI":"10.1074\/jbc.M107069200","article-title":"Differential regulation of akt kinase isoforms by the members of the tcl1 oncogene family","volume":"277","author":"Laine","year":"2002","journal-title":"J. Biol. Chem."},{"issue":"Pt 1","key":"10.1016\/j.biopha.2020.110107_bib0370","first-page":"1","article-title":"Signal-dependent membrane targeting by pleckstrin homology (PH) domains","volume":"350","author":"Lemmon","year":"2000","journal-title":"Biochem. J."},{"key":"10.1016\/j.biopha.2020.110107_bib0375","first-page":"6297","article-title":"Characterization and localization of the TCL-1 oncogene product","volume":"4","author":"Fu","year":"1994","journal-title":"Cancer Res."},{"issue":"7","key":"10.1016\/j.biopha.2020.110107_bib0380","first-page":"1957","article-title":"The proteins encoded by c-akt and v-akt differ in post-translational modification, subcellular localization and oncogenic potential","volume":"8","author":"Ahmed","year":"1993","journal-title":"Oncogene"},{"issue":"50","key":"10.1016\/j.biopha.2020.110107_bib0385","doi-asserted-by":"crossref","first-page":"31515","DOI":"10.1074\/jbc.272.50.31515","article-title":"Role of translocation in the activation and function of protein kinase B","volume":"272","author":"Andjelkovic","year":"1997","journal-title":"J. Biol. Chem."},{"issue":"26","key":"10.1016\/j.biopha.2020.110107_bib0390","doi-asserted-by":"crossref","first-page":"3733","DOI":"10.1038\/onc.2010.139","article-title":"Targeting mTOR: prospects for mTOR complex 2 inhibitors in cancer therapy","volume":"29","author":"Sparks","year":"2010","journal-title":"Oncogene"},{"issue":"9","key":"10.1016\/j.biopha.2020.110107_bib0395","doi-asserted-by":"crossref","DOI":"10.1038\/oncsis.2013.30","article-title":"Protooncogene TCL1b functions as an Akt kinase co-activator that exhibits oncogenic potency in vivo","volume":"2","author":"Hashimoto","year":"2013","journal-title":"Oncogenesis"},{"key":"10.1016\/j.biopha.2020.110107_bib0400","doi-asserted-by":"crossref","first-page":"9133","DOI":"10.1074\/jbc.274.14.9133","article-title":"A human protein kinase B\u03b3 with regulatory phosphorylation sites in the activation loop and in the C-terminal hydrophobic domain","volume":"274","author":"Brodbeck","year":"1999","journal-title":"J. Biol. Chem."},{"issue":"16","key":"10.1016\/j.biopha.2020.110107_bib0405","doi-asserted-by":"crossref","first-page":"2502","DOI":"10.4161\/cc.8.16.9335","article-title":"The Akt kinases: isoform specificity in metabolism and cancer","volume":"8","author":"Gonzalez","year":"2009","journal-title":"Cell Cycle"},{"issue":"13","key":"10.1016\/j.biopha.2020.110107_bib0410","doi-asserted-by":"crossref","first-page":"4406","DOI":"10.1182\/blood-2006-11-059501","article-title":"The TCL1 oncoprotein inhibits activation-induced cell death by impairing PKC\u03b8 and ERK pathways","volume":"110","author":"Despouy","year":"2007","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.biopha.2020.110107_bib0415","doi-asserted-by":"crossref","first-page":"4997","DOI":"10.1016\/S0021-9258(18)53494-3","article-title":"Molecular cloning and characterization of PKC theta, a novel member of the protein kinase C (PKC) gene family expressed predominantly in hematopoietic cells","volume":"268","author":"Baier","year":"1993","journal-title":"J. Biol. Chem."},{"issue":"19","key":"10.1016\/j.biopha.2020.110107_bib0420","doi-asserted-by":"crossref","first-page":"14208","DOI":"10.1016\/S0021-9258(19)85228-6","article-title":"Molecular cloning and expression of a cDNA encoding a novel isoenzyme of protein kinase C (nPKC). A new member of the nPKC family expressed in skeletal muscle, megakaryoblastic cells, and platelets","volume":"268","author":"Chang","year":"1993","journal-title":"J. Biol. Chem."},{"issue":"6","key":"10.1016\/j.biopha.2020.110107_bib0425","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/j.phrs.2007.04.009","article-title":"Protein kinase C theta (PKCtheta): a key player in T cell life and death","volume":"55","author":"Hayashi","year":"2007","journal-title":"Pharmacol. Res."},{"issue":"4","key":"10.1016\/j.biopha.2020.110107_bib0430","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1007\/s11912-017-0581-x","article-title":"Prolymphocytic leukemia: new insights in diagnosis and in treatment","volume":"19","author":"Collignon","year":"2017","journal-title":"Curr. Oncol. Rep."},{"issue":"3","key":"10.1016\/j.biopha.2020.110107_bib0435","doi-asserted-by":"crossref","first-page":"234","DOI":"10.3816\/CLM.2005.n.051","article-title":"T-cell prolymphocytic leukemia: a single-institution experience","volume":"6","author":"Ravandi","year":"2005","journal-title":"Clin. Lymphoma Myeloma"},{"issue":"3","key":"10.1016\/j.biopha.2020.110107_bib0440","doi-asserted-by":"crossref","first-page":"e65","DOI":"10.1111\/ijd.13457","article-title":"Linear nonpalpable purpura in a young male: a unique presentation of leukemia cutis in T-cell prolymphocytic leukemia","volume":"56","author":"Khullar","year":"2017","journal-title":"Int. J. Dermatol."},{"issue":"3","key":"10.1016\/j.biopha.2020.110107_bib0445","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1080\/09273948.2016.1216129","article-title":"Intraocular T-cell prolymphocytic leukemia masquerading as necrotizing herpetic retinitis","volume":"26","author":"Krassas","year":"2018","journal-title":"Ocul. Immunol. Inflamm."},{"issue":"6","key":"10.1016\/j.biopha.2020.110107_bib0450","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1182\/blood.V98.6.1721","article-title":"High remission rate in T-cell prolymphocytic leukemia with CAMPATH-1H","volume":"98","author":"Dearden","year":"2001","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.biopha.2020.110107_bib0455","doi-asserted-by":"crossref","first-page":"942","DOI":"10.3109\/10428194.2015.1076932","article-title":"Survival trends in T cell prolymphocytic leukemia: a SEER database analysis","volume":"57","author":"Chandran","year":"2016","journal-title":"Leuk. Lymphoma"},{"issue":"12","key":"10.1016\/j.biopha.2020.110107_bib0460","doi-asserted-by":"crossref","first-page":"2588","DOI":"10.1200\/JCO.1994.12.12.2588","article-title":"The role of pentostatin in the treatment of T-cell malignancies: analysis of response rate in 145 patients according to disease subtype","volume":"12","author":"Mercieca","year":"1994","journal-title":"J. Clin. Oncol."},{"issue":"12","key":"10.1016\/j.biopha.2020.110107_bib0465","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1023\/A:1008377724139","article-title":"Pentostatin in T-cell malignancies--a phase II trial of the EORTC. Leukemia Cooperative Group","volume":"10","author":"Ho","year":"1999","journal-title":"Ann. Oncol."},{"issue":"12","key":"10.1016\/j.biopha.2020.110107_bib0470","doi-asserted-by":"crossref","first-page":"2258","DOI":"10.1002\/cncr.27972","article-title":"Sequential chemoimmunotherapy of fludarabine, mitoxantrone, and cyclophosphamide induction followed by alemtuzumab consolidation is effective in T-cell prolymphocytic leukemia","volume":"119","author":"Hopfinger","year":"2013","journal-title":"Cancer"},{"issue":"6","key":"10.1016\/j.biopha.2020.110107_bib0475","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1111\/j.1365-2141.2010.08134.x","article-title":"Stem cell transplantation after alemtuzumab in T-cell prolymphocytic leukaemia results in longer survival than after alemtuzumab alone: a multicentre retrospective study","volume":"149","author":"Krishnan","year":"2010","journal-title":"Br. J. Haematol."},{"issue":"7","key":"10.1016\/j.biopha.2020.110107_bib0480","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1200\/JCO.2007.14.1986","article-title":"Phase I trial of nelarabine in indolent leukemias","volume":"26","author":"Gandhi","year":"2008","journal-title":"J. Clin. Oncol."},{"issue":"6","key":"10.1016\/j.biopha.2020.110107_bib0485","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1111\/bjh.13175","article-title":"Bendamustine is effective in T-cell prolymphocytic leukaemia","volume":"168","author":"Herbaux","year":"2015","journal-title":"Br. J. Haematol."},{"issue":"8","key":"10.1016\/j.biopha.2020.110107_bib0490","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1093\/jnci\/85.8.658","article-title":"Pentostatin in prolymphocytic leukemia: phase II trial of the european organization for research and treatment of cancer leukemia cooperative study group","volume":"85","author":"D\u00f6hner","year":"1993","journal-title":"J. Natl. Cancer Inst."},{"issue":"15","key":"10.1016\/j.biopha.2020.110107_bib0495","first-page":"3352","article-title":"2-amino-6-methoxypurine arabinoside: an agent for T-cell malignancies","volume":"55","author":"Lambe","year":"1995","journal-title":"Cancer Res."},{"issue":"15","key":"10.1016\/j.biopha.2020.110107_bib0500","doi-asserted-by":"crossref","first-page":"3376","DOI":"10.1200\/JCO.2005.03.426","article-title":"Phase II study of nelarabine (compound 506U78) in children and young adults with refractory T-cell malignancies: a report from the Children\u2019s Oncology Group","volume":"23","author":"Berg","year":"2005","journal-title":"J. Clin. Oncol."},{"issue":"18","key":"10.1016\/j.biopha.2020.110107_bib0505","doi-asserted-by":"crossref","first-page":"5329","DOI":"10.1158\/1078-0432.CCR-06-0606","article-title":"Approval summary: nelarabine for the treatment of T-Cell lymphoblastic leukemia\/lymphoma","volume":"12","author":"Cohen","year":"2006","journal-title":"Clin. Cancer Res."},{"issue":"15","key":"10.1016\/j.biopha.2020.110107_bib0510","doi-asserted-by":"crossref","first-page":"3396","DOI":"10.1200\/JCO.2005.03.199","article-title":"Phase I study of 506U78 administered on a consecutive 5-day schedule in children and adults with refractory hematologic malignancies","volume":"23","author":"Kurtzberg","year":"2005","journal-title":"J. Clin. Oncol."},{"issue":"9","key":"10.1016\/j.biopha.2020.110107_bib0515","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1007\/s00277-013-1746-9","article-title":"Bendamustine salvage therapy for T cell neoplasms","volume":"92","author":"Zaja","year":"2013","journal-title":"Ann. Hematol."},{"issue":"1","key":"10.1016\/j.biopha.2020.110107_bib0520","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1200\/JCO.2012.43.7285","article-title":"Results from a prospective, open-label, phase II trial of Bendamustine in refractory or relapsed T-Cell lymphomas: the BENTLY trial","volume":"31","author":"Damaj","year":"2013","journal-title":"J. Clin. Oncol."},{"issue":"7","key":"10.1016\/j.biopha.2020.110107_bib0525","doi-asserted-by":"crossref","first-page":"2667","DOI":"10.1200\/JCO.1997.15.7.2667","article-title":"Treatment of T-cell prolymphocytic leukemia with human CD52 antibody","volume":"15","author":"Pawson","year":"1997","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.biopha.2020.110107_bib0530","doi-asserted-by":"crossref","first-page":"5799","DOI":"10.1182\/blood-2011-08-372854","article-title":"Alemtuzumab therapy in T-cell prolymphocytic leukemia: comparing efficacy in a series treated intravenously and a study piloting the subcutaneous route","volume":"118","author":"Dearden","year":"2011","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.biopha.2020.110107_bib0535","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1200\/JCO.2002.20.1.205","article-title":"Campath-1H treatment of T-Cell prolymphocytic leukemia in patients for whom at least one prior chemotherapy regimen has failed","volume":"20","author":"Keating","year":"2002","journal-title":"J. Clin. Oncol."},{"issue":"32","key":"10.1016\/j.biopha.2020.110107_bib0540","doi-asserted-by":"crossref","first-page":"5425","DOI":"10.1200\/JCO.2009.22.6688","article-title":"Phase II study of alemtuzumab in combination with pentostatin in patients with T-cell neoplasms","volume":"27","author":"Ravandi","year":"2009","journal-title":"J. Clin. Oncol."},{"issue":"6","key":"10.1016\/j.biopha.2020.110107_bib0545","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1038\/sj.bmt.1701127","article-title":"Treatment of T prolymphocytic leukemia with allogeneic bone marrow transplantation","volume":"21","author":"Collins","year":"1998","journal-title":"Bone Marrow Transplant."},{"issue":"2","key":"10.1016\/j.biopha.2020.110107_bib0550","first-page":"137","article-title":"Treatment of T\u2010prolymphocytic leukemia with nonmyeloablative allogeneic stem cell transplantation","volume":"66","author":"Garderet","year":"2001","journal-title":"Eur. J. Haematol."},{"issue":"7","key":"10.1016\/j.biopha.2020.110107_bib0555","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1038\/sj.bmt.1705294","article-title":"Allogeneic stem cell transplantation after reduced-intensity conditioning in a patient with T-cell prolymphocytic leukemia: graft-versus-tumor effect and long-term remission","volume":"37","author":"de Lavallade","year":"2006","journal-title":"Bone Marrow Transplant."},{"issue":"11","key":"10.1016\/j.biopha.2020.110107_bib0560","first-page":"882","article-title":"Successful treatment of T-cell prolymphocytic leukemia with full-intensity conditioning followed by matched unrelated donor allogeneic stem cell transplantation","volume":"5","author":"Kruspe","year":"2007","journal-title":"Clin. Adv. Hematol. Oncol."},{"issue":"4","key":"10.1016\/j.biopha.2020.110107_bib0565","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1038\/sj.leu.2403669","article-title":"Mismatched unrelated cord blood transplantation in a patient with T-cell prolymphocytic leukemia","volume":"19","author":"Tanimoto","year":"2005","journal-title":"Leukemia"},{"issue":"6","key":"10.1016\/j.biopha.2020.110107_bib0570","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1007\/s10147-003-0349-1","article-title":"Allogeneic bone marrow transplantation in a patient with T-prolymphocytic leukemia with small-intestinal involvement","volume":"8","author":"Murase","year":"2003","journal-title":"Int. J. Clin. Oncol."},{"issue":"5","key":"10.1016\/j.biopha.2020.110107_bib0575","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1038\/leu.2011.304","article-title":"Hematopoietic stem cell transplantation in T-prolymphocytic leukemia: a retrospective study from the European Group for Blood and Marrow Transplantation and the Royal Marsden Consortium","volume":"26","author":"Wiktor-Jedrzejczak","year":"2012","journal-title":"Leukemia"},{"issue":"4","key":"10.1016\/j.biopha.2020.110107_bib0580","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/j.bbmt.2009.11.021","article-title":"Allogeneic hematopoietic cell transplant for prolymphocytic leukemia","volume":"16","author":"Kalaycio","year":"2010","journal-title":"Biol. Blood Marrow Transplant."},{"issue":"3","key":"10.1016\/j.biopha.2020.110107_bib0585","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1111\/ejh.12430","article-title":"Allogeneic hematopoietic stem cell transplantation for T-prolymphocytic leukemia: a report from the French society for stem cell transplantation (SFGM-TC)","volume":"94","author":"Guillaume","year":"2015","journal-title":"Eur. J. Haematol."},{"issue":"4","key":"10.1016\/j.biopha.2020.110107_bib0590","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1038\/bmt.2017.12","article-title":"GvL effects in T-prolymphocytic leukemia: evidence from MRD kinetics and TCR repertoire analyses","volume":"52","author":"Sellner","year":"2017","journal-title":"Bone Marrow Transplant."},{"issue":"3","key":"10.1016\/j.biopha.2020.110107_bib0595","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1111\/ejh.12462","article-title":"Are we improving the outcome for patients with T-cell prolymphocytic leukemia by allogeneic stem cell transplantation?","volume":"94","author":"Herling","year":"2015","journal-title":"Eur. J. Haematol."},{"issue":"9","key":"10.1016\/j.biopha.2020.110107_bib0600","doi-asserted-by":"crossref","first-page":"2213","DOI":"10.1007\/s00277-019-03759-y","article-title":"Effect of allogeneic hematopoietic cell transplantation for patients with T-prolymphocytic leukemia: a retrospective study from the adult lymphoma working Group of the Japan Society for hematopoietic cell transplantation","volume":"98","author":"Yamasaki","year":"2019","journal-title":"Ann. Hematol."},{"issue":"9","key":"10.1016\/j.biopha.2020.110107_bib0605","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1038\/s41409-019-0448-x","article-title":"EBMT prospective observational study on allogeneic hematopoietic stem cell transplantation in T-prolymphocytic leukemia (T-PLL)","volume":"54","author":"Wiktor-Jezejczak","year":"2019","journal-title":"Bone Marrow Transplant."},{"issue":"10","key":"10.1016\/j.biopha.2020.110107_bib0610","doi-asserted-by":"crossref","first-page":"1666","DOI":"10.1021\/cb300281t","article-title":"Isolation and functional characterization of peptide agonists of PTPRJ, a tyrosine phosphatase receptor endowed with tumor suppressor activity","volume":"7","author":"Paduano","year":"2012","journal-title":"ACS Chem. Biol."},{"issue":"7","key":"10.1016\/j.biopha.2020.110107_bib0615","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1021\/cb3007192","article-title":"Discovery of PTPRJ agonist peptides that effectively inhibit in vitro cancer cell proliferation and tube formation","volume":"8","author":"Ortuso","year":"2013","journal-title":"ACS Chem. Biol."},{"issue":"51","key":"10.1016\/j.biopha.2020.110107_bib0620","doi-asserted-by":"crossref","first-page":"53407","DOI":"10.1074\/jbc.M403775200","article-title":"Inhibition of Akt kinase activity by a peptide spanning the betaA strand of the proto-oncogene TCL1","volume":"279","author":"Hiromura","year":"2004","journal-title":"J. Biol. Chem."},{"issue":"8","key":"10.1016\/j.biopha.2020.110107_bib0625","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1182\/blood-2011-09-382838","article-title":"TCL1: a shared tumor-associated antigen for immunotherapy against B-cell lymphomas","volume":"120","author":"Weng","year":"2012","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.biopha.2020.110107_bib0630","doi-asserted-by":"crossref","first-page":"e2071","DOI":"10.1038\/cddis.2015.419","article-title":"TCL1 transgenic mouse model as a tool for the study of therapeutic targets and microenvironment in human B-cell chronic lymphocytic leukemia","volume":"7","author":"Bresin","year":"2016","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.biopha.2020.110107_bib0635","doi-asserted-by":"crossref","first-page":"1876","DOI":"10.1100\/tsw.2002.826","article-title":"Crystal structures of Tcl1 family oncoproteins and their conserved surface features","volume":"2","author":"Petock","year":"2002","journal-title":"Sci. World J."},{"issue":"5","key":"10.1016\/j.biopha.2020.110107_bib0640","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1084\/jem.20021101","article-title":"Critical roles of Pten in B cell homeostasis and immunoglobulin class switch recombination","volume":"197","author":"Suzuki","year":"2003","journal-title":"J. Exp. Med."},{"issue":"9","key":"10.1016\/j.biopha.2020.110107_bib0645","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1182\/blood-2014-03-559542","article-title":"Integrated genomic sequencing reveals mutational landscape of T-cell prolymphocytic leukemia","volume":"124","author":"Kiel","year":"2014","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.biopha.2020.110107_bib0650","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1038\/leu.2013.271","article-title":"Recurrent JAK1 and JAK3 somatic mutations in T-cell prolymphocytic leukemia","volume":"28","author":"Bellanger","year":"2014","journal-title":"Leukemia"},{"issue":"26","key":"10.1016\/j.biopha.2020.110107_bib0655","doi-asserted-by":"crossref","first-page":"3924","DOI":"10.1182\/blood-2014-05-576652","article-title":"Cooperating JAK1 and JAK3 mutants increase resistance to JAK inhibitors","volume":"124","author":"Springuel","year":"2014","journal-title":"Blood"},{"issue":"20","key":"10.1016\/j.biopha.2020.110107_bib0660","doi-asserted-by":"crossref","first-page":"3092","DOI":"10.1182\/blood-2014-04-566687","article-title":"JAK3 mutants transform hematopoietic cells through JAK1 activation, causing T-cell acute lymphoblastic leukemia in a mouse model","volume":"124","author":"Degryse","year":"2014","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.biopha.2020.110107_bib0665","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1038\/ng.518","article-title":"Somatic mutations altering EZH2 (Tyr641) in follicular and diffuse large B-cell lymphomas of germinal-center origin","volume":"42","author":"Morin","year":"2010","journal-title":"Nat. Genet."},{"issue":"7360","key":"10.1016\/j.biopha.2020.110107_bib0670","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1038\/nature10351","article-title":"Frequent mutation of histone-modifying genes in non-hodgkin lymphoma","volume":"476","author":"Morin","year":"2011","journal-title":"Nature"},{"issue":"2","key":"10.1016\/j.biopha.2020.110107_bib0675","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1038\/ng.2856","article-title":"Integrated genomic analysis identifies recurrent mutations and evolution patterns driving the initiation and progression of follicular lymphoma","volume":"46","author":"Okosun","year":"2014","journal-title":"Nat. Genet."}],"container-title":["Biomedicine & Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332220302997?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332220302997?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,6,25]],"date-time":"2025-06-25T19:39:22Z","timestamp":1750880362000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0753332220302997"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6]]},"references-count":135,"alternative-id":["S0753332220302997"],"URL":"https:\/\/doi.org\/10.1016\/j.biopha.2020.110107","relation":{},"ISSN":["0753-3322"],"issn-type":[{"value":"0753-3322","type":"print"}],"subject":[],"published":{"date-parts":[[2020,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Current understandings on T-cell prolymphocytic leukemia and its association with TCL1 proto-oncogene","name":"articletitle","label":"Article Title"},{"value":"Biomedicine & Pharmacotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopha.2020.110107","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 The Authors. Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"110107"}}